Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia

Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia

Abstract Resistance to chemotherapy remains a formidable obstacle in acute myeloid leukemia (AML) therapeutic management, necessitating the exploration of optimal strategies to maximize therapeutic benefits. Venetoclax with 3+7 daunorubicin and cytarabine (DAV regimen) in young adult de novo AML pat...

Full description

Bibliographic Details
Main Authors: Jie Jin, Shangyu Hou, Yiyi Yao, Miaomiao Liu, Liping Mao, Min Yang, Hongyan Tong, Tao Zeng, Jinyan Huang, Yinghui Zhu, Huafeng Wang
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Advanced Science
Subjects:
acute myeloid leukemia
AKT1
AURKB
drug resistance
venetoclax
Online Access:https://doi.org/10.1002/advs.202305885

Similar Items

Similar Items